Antithrombotic Therapy in Blunt Cerebrovascular Injury: Associations With In-Hospital Mortality in a Contemporary Trauma Cohort
- 29 July 2026
- journal article
- research article
- Published by SAGE Publications in The American Surgeon™
- Vol. 92 (12) , 3477-3480
Abstract
At our institution, aspirin (ASA) is the recommended treatment for blunt cerebrovascular injury (BCVI), and low molecular weight heparin (LMWH) is the preferred agent for venous thromboembolism prophylaxis. While both therapies are widely used and individually safe, evidence regarding their combined use in BCVI patients is limited. This study evaluated the safety of concurrent LMWH and ASA therapy in trauma patients with BCVI. Materials and Methods: We analyzed trauma admissions from 2021-2024 using the institutional trauma registry and an electronic medical record–based data warehouse at an adult Level I trauma center. Patients with and without BCVI were included. Univariate and bivariate analyses were performed using Student’s t-tests and chi-square tests, and multivariable logistic regression assessed associations between BCVI, medication use, and in-hospital mortality. Results: Among 4,306 included patients, 365 (8.5%) had BCVI. The mean age was 42 years, 36% were female, and 59% were White. After adjustment, BCVI was associated with increased odds of in-hospital mortality (OR 2.03, 95% CI 1.14-3.61, P = 0.015). Among patients with BCVI, treatment with LMWH alone, ASA alone, or combined LMWH and ASA was associated with significantly lower odds of in-hospital death (LMWH OR 0.09; ASA OR 0.29; combination OR 0.20; all P < 0.05). Discussion: Although BCVI occurred in fewer than one in twelve patients, it was associated with more than double the odds of mortality. Medical therapy, including combined antiplatelet and anticoagulant treatment, appears to be safe for use in BCVI patients.Keywords
This publication has 11 references indexed in Scilit:
- American Association for the Surgery of Trauma—World Society of Emergency Surgery Guidelines on the diagnosis and management of cervical vascular injuriesJournal of Trauma and Acute Care Surgery, 2026
- Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma PatientsThe American Surgeon™, 2024
- Antiplatelets versus anticoagulants in the treatment of blunt cerebrovascular injury (BCVI) – A systematic review and meta-analysisInjury, 2024
- The silent killer: Previously undetected pulmonary emboli that result in death after dischargeInjury, 2023
- Efficacy of Antithrombotic Therapy and Risk of Hemorrhagic Complication in Blunt Cerebrovascular Injury Patients with Concomitant Injury: A Systematic ReviewJournal of the American College of Surgeons, 2023
- Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a FractureNew England Journal of Medicine, 2023
- Approaches for optimizing venous thromboembolism prevention in injured patients: Findings from the consensus conference to implement optimal venous thromboembolism prophylaxis in traumaJournal of Trauma and Acute Care Surgery, 2022
- American Association for the Surgery of Trauma/American College of Surgeons-Committee on Trauma Clinical Protocol for inpatient venous thromboembolism prophylaxis after traumaJournal of Trauma and Acute Care Surgery, 2021
- Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithmJournal of Trauma and Acute Care Surgery, 2020
- Evaluation and management of blunt cerebrovascular injury: A practice management guideline from the Eastern Association for the Surgery of TraumaJournal of Trauma and Acute Care Surgery, 2020